SEARCH

SEARCH BY CITATION

References

  • 1
    Gómez-Reino JJ, Carmona L, Rodríguez V et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. Arthritis Rheum 2003; 48:21222127.
  • 2
    Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345:10981104.
  • 3
    Wallis RS, Broder MS, Wong JY et al. Granulomatous infection diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:12611265.
  • 4
    Winthrop KL, Weinblatt ME, Daley CL. You can't always get what you want, but if you try sometimes (with two tests – TST and IGRA – for tuberculosis) you get what you need. Ann Rheum Dis 2012; 71:17571760.
  • 5
    Sauzullo I, Mengoni F, Scrivo R et al. Evaluation of QuantiFERON-TB Gold In-Tube in human immunodeficiency virus infection and in patient candidates for anti-tumour necrosis factor-alpha treatment. Int J Tuberc Lung Dis 2010; 14:834840.
  • 6
    Santin M, Muñoz L, Rigau D. Interferon-γ release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis. PLOS ONE 2012; 7:e32482.
  • 7
    Hamdi H, Mariette X, Godot V et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 2006; 8:R114.
  • 8
    Chen DY, Shen GH, Hsieh TY et al. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 2008; 59:800806.
  • 9
    Matulis G, Juni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases performance of a Mycobacterium tuberculosis antigen specific IFN-gamma assay. Ann Rheum Dis 2008; 67:8490.
  • 10
    Scrivo R, Sauzullo I, Mengoni F et al. Mycobacterial interferon-γ release variations during longterm treatment with tumor necrosis factor blockers: lack of correlation with clinical outcome. J Rheumatol 2013; 40:157165.
  • 11
    Zwerling A, van den Hof S, Scholten J et al. Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review. Thorax 2012; 67:6270.
  • 12
    Sauzullo I, Mengoni F, Marocco R et al. IFN-γ release assay for tuberculosis in psoriasis patients treated with TNF antagonists: in vivo and in vitro analysis. Br J Dermatol 2013; 169:11331140.
  • 13
    Ringrose JS, Sanche SE, Taylor-Gjevre RM. Detecting latent tuberculosis infection during anti-tumor necrosis factor therapy. Clin Exp Rheumatol 2011; 29:790794.
  • 14
    Garcovich S, Ruggeri A, D'Agostino M et al. Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study. J Eur Acad Dermatol Venereol 2012; 26:15721576.
  • 15
    Kim KH, Lee SW, Chung WT et al. Serial interferon-gamma release assays for the diagnosis of latent tuberculosis infection in patients treated with immunosuppressive agents. Korean J Lab Med 2011; 31:271278.
  • 16
    Chen DY, Shen GH, Chen YM et al. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNF (alpha) inhibitors: the utility of IFN (gamma) assay. Ann Rheum Dis 2012; 71:231237.
  • 17
    Xie X, Chen JW, Li F, Tian J, Gao JS, Zhang D. A T-cell-based enzyme-linked immunospot assay for tuberculosis screening in Chinese patients with rheumatic diseases receiving infliximab therapy. Clin Exp Med 2011; 11:155161.
  • 18
    Klein M, Jarosová K, Forejtová S et al. Quantiferon TB Gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents. Clin Exp Rheumatol 2013; 31:111117.
  • 19
    Caccamo N, Guggino G, Joosten SA et al. Multifunctional CD4+ T cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol 2010; 40:22112220.
  • 20
    Sester U, Fousse M, Dirks J et al. Whole-blood flow-cytometric analysis of antigen-specific CD4 T-cell cytokine profiles distinguishes active tuberculosis from non-active states. PLOS ONE 2011; 6:e17813.
  • 21
    Lee J, Lee SY, Won DI et al. Comparison of whole-blood interferon-γ assay and flow cytometry for the detection of tuberculosis infection. J Infect 2013; 66:338345.
  • 22
    American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161:S221247.
  • 23
    Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52:17661772.
  • 24
    Tesfa L, Koch FW, Pankow W et al. Confirmation of Mycobacterium tuberculosis infection by flow cytometry after ex vivo incubation of peripheral blood T cells with an ESAT-6-derived peptide pool. Cytometry B Clin Cytom 2004; 60:4753.
  • 25
    Hughes AJ, Hutchinson P, Gooding T et al. Diagnosis of Mycobacterium tuberculosis infection using ESAT-6 and intracellular cytokine cytometry. Clin Exp Immunol 2005; 142:132139.
  • 26
    Cosmi L, Maggi L, Santarlasci V et al. Detection by flow cytometry of ESAT-6- and PPD-specific circulating CD4+ T lymphocytes as a diagnostic tool for tuberculosis. Int Arch Allergy Immunol 2007; 143:19.
  • 27
    Leung WL, Law KL, Leung VS et al. Comparison of intracellular cytokine flow cytometry and an enzyme immunoassay for evaluation of cellular immune response to active tuberculosis. Clin Vaccine Immunol 2009; 16:344351.
  • 28
    Won DI, Park JR. Flow cytometric measurements of TB-specific T cells comparing with QuantiFERON-TB gold. Cytometry B Clin Cytom 2010; 78:7180.
  • 29
    Sargentini V, Mariotti S, Carrara S et al. Cytometric detection of antigen-specific IFNgamma/IL-2 secreting cells in the diagnosis of tuberculosis. BMC Infect Dis 2009; 9:99109.
  • 30
    Streitz M, Fuhrmann S, Powell F et al. Tuberculin-specific T cells are reduced in active pulmonary tuberculosis compared to LTBI or status post BCG vaccination. J Infect Dis 2011; 203:378382.
  • 31
    Petruccioli E, Petrone L, Vanini V et al. IFNγ/TNFα specific-cells and effector memory phenotype associate with active tuberculosis. J Infect 2013; 66:475486.
  • 32
    Harari A, Rozot V, Enders FB et al. Dominant TNF-alpha Mycobacterium tuberculosis specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med 2011; 17:372376.
  • 33
    Commandeur S, Lin MY, van Meijgaarden KE et al. Double-and monofunctional CD4+ and CD8+ T-cell responses to Mycobacterium tuberculosis DosR antigens and peptides in long-term latently infected individuals. Eur J Immunol 2011; 41:29252936.
  • 34
    Day CL, Mkhwanazi N, Reddy S et al. Detection of polyfunctional Mycobacterium tuberculosis-specific T cells and association with viral load in HIV-1-infected persons. J Infect Dis 2008; 197:990999.
  • 35
    Gardam MA, Keystone EC, Menzies R et al. Anti-tumor necrosis factor agents and tuberculosis risk: mechanism of action and clinical management. Lancet Infect Dis 2003; 3:148155.
  • 36
    Seder RA, Darra PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8:247258.